Amerikanische Gesellschaft für Hirudotherapie

Heparin Induced Thrombocytopenia In The Setting Of Urgent Cardiac Surgery: Can Bivalirudin Be A Safe Option? - A Case Report

Case report published in Portuguese Journal of Cardiac Thoracic and Vascular Surgery (2025)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportArzneimittelentwicklungAlves B et al. · Portuguese Journal of Cardiac Thoracic and Vascular Surgery, 2025

Abstract

Unfractionated heparin is the main anticoagulant employed in the context of cardiovascular surgery. When a patient with heparin induced thrombocytopenia (HIT) is proposed for cardiac surgery, the anticoagulation management is challenging. Bivalirudin is an alternative to heparin in the perioperative setting. We present a rare case of a patient with HIT and cardiogenic shock that required bivalirudin use in the perioperative period of an urgent reoperation of recurrent mitral valve dysfunction. Although infrequent, the use of bivalirudin can be safe in high risk patients if adequate measures follow institutional protocols, as reported in this case.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleCase Reports
Indexed MeSH termsHumansAnticoagulantsAntithrombinsHeart Valve Prosthesis ImplantationHeparinHirudinsMitral Valve InsufficiencyPeptide FragmentsRecombinant ProteinsReoperationShock, CardiogenicThrombocytopenia

Zusammenfassung

Heparin Induced Thrombocytopenia In The Setting Of Urgent Cardiac Surgery: Can Bivalirudin Be A Safe Option? - A Case Report.

Warum dies für die Hirudotherapie relevant ist

This case report describes a patient with heparin-induced thrombocytopenia (HIT) and cardiogenic shock who received bivalirudin during the perioperative period of an urgent reoperation for recurrent mitral valve dysfunction, with a reportedly safe outcome under institutional protocols. The abstract discusses bivalirudin as an alternative to heparin in the perioperative setting but provides no detail on its mechanism beyond clinical use. For ASH, no defensible leech or hirudotherapy connection exists from the abstract: it does not mention leeches, hirudin, or leech-derived therapy. Honest caveat: this is a single case report involving no leeches or leech therapy, and it does not establish efficacy or safety beyond the described individual.

Zitation

Heparin Induced Thrombocytopenia In The Setting Of Urgent Cardiac Surgery: Can Bivalirudin Be A Safe Option? - A Case Report

Alves B et al. · Portuguese Journal of Cardiac Thoracic and Vascular Surgery, 2025

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.